Beyond Air Sells NeuroNOS Stake for Equity and Milestone Payments
XAIR is trading near its 52-week low of $4.85 (1.5% below the low).
Summary
Beyond Air has entered a definitive agreement to sell its NeuroNOS stake to UNIVO Pharmaceutical Industries in exchange for equity and milestone payments. The divestiture provides non-dilutive capital and potential future upside while allowing the company to focus on its core nitric oxide platform. The deal follows a period of financial strain, including a going concern warning and only $9.8 million in cash as of the latest 10-Q. The equity component gives Beyond Air exposure to UNIVO's growth, and milestone payments could provide additional liquidity if development targets are met. Terms of the equity stake and milestone thresholds were not disclosed.
At the time of this announcement, XAIR was trading at $4.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $4.85 to $95.60. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.